HTLV-1 persistence and the oncogenesis of adult T cell leukemia/lymphoma

by | Feb 18, 2023 | Publications

Blood. 2023 Feb 17:blood.2022019332. doi: 10.1182/blood.2022019332. Online ahead of print.


Human T-cell leukemia virus type 1 (HTLV-1), also known as human T-lymphotropic virus type 1, causes the aggressive malignancy known as adult T-cell leukemia/lymphoma (ATL) in 5% of infected people, and a chronic progressive inflammatory disease of the central nervous system – HTLV-1-associated myelopathy (HAM) – in a further 0.3% to 4%, varying between endemic regions. Reliable treatments are lacking for both conditions, although there have been promising recent advances in the prevention and treatment of ATL. Since ATL typically develops after several decades of infection, it is necessary to understand how the virus persists in the host despite a strong immune response, and how this persistence results in oncogenesis.

PMID:36800643 | DOI:10.1182/blood.2022019332

Other publications you may be interested in…

HTLV-1 Disease

HTLV-1 Disease

HTLV-1 Disease Abstract The years 2020 and 2021 will remain memorable years for many reasons [...]. Click here to...

read more